True Leaf Medicine International Ltd.
True Leaf Announces Private Placement
DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Capital Increase/Regulatory Approval For Immediate Release NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. True Leaf Announces Private Placement Vancouver, BC, May 3, 2017 – True Leaf Medicine International Ltd. (the “Company“) (MJ: CSE)(TLA: FSE) is pleased to announce that it intends to complete a non-brokered private placement of units of the company (each, a “Unit“) at a price of C$0.30 per Unit, with each Unit being comprised of one common share of the Company (a “Common Share“) and one warrant exercisable into one Common Share at an exercise price of $0.45 per Common Share for a period of 24 months (the “Offering“) for aggregate gross proceeds of up to C$3,000,000. All or a portion of the Offering may be completed pursuant to Multilateral CSA Notice 45-318 Prospectus Exemption for Certain Distributions through an Investment Dealer (“CSA 45-318“) and the corresponding instruments, orders and rules implementing CSA 45-318 in the participating jurisdictions (collectively with CSA 45-318, the “Investment Dealer Exemption“). In order for the Company to be able to rely on the Investment Dealer Exemption, each subscriber must purchase the Units as principal and obtain advice regarding the suitability of the investment from a person who is registered as an investment dealer in the jurisdiction in which the subscriber is resident. The Company intends to use the proceeds of the Offering as follows: True Leaf Medicine Inc.: Federal Medicinal Cannabis License applicant under the ‘ACMPR’ True Leaf Pet True Leaf Pet Europe There is no material fact or material change about the Company that has not been generally disclosed. There is no minimum subscription amount for the Offering, and the securities underlying the Units issued pursuant to the Offering will be subject to a four month and one day hold period in accordance with applicable securities laws. The Company may pay a cash finder’s fee to eligible persons equal to 7% of the gross proceeds raised from applicable subscribers in the Offering. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the United States except in compliance with one or more exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. For more information, please see the Company’s website at www.trueleaf.com Media Contact: Forward-Looking Information:
03.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | True Leaf Medicine International Ltd. |
32 – 100 Kalamalka Lake Road | |
V1T 9 G1 Vernon (BC) | |
Canada | |
Phone: | +17783899933 |
E-mail: | kevin@trueleaf.com |
Internet: | www.trueleaf.com |
ISIN: | CA89785C1077, CA89785C1077 |
WKN: | , A0Q3EE |
Listed: | Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt; Canadian Venture Exchange |
End of News | DGAP News Service |